ABBVAbbVieRunning, no new patients
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 270 (final count)
- Started
- Oct 10, 2018
- Main results expected
- Jul 2026
- Fully finished
- Aug 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) (Stage 1 and Stage 2)
Measured over: Up to approximately 3 years
Number of Participants with Adverse Events (Alternate dose cohort)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03539536 · record last updated 2025-11-05 · checked 2026-11-09 15:47 UTC